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Abstract
 
The contribution of the latent antigen-specific CD8
 
1
 
 T cell response to the control of gamma-
herpesvirus latency is currently obscure. Some latent antigens induce potent T cell responses,
but little is known about their induction or the role they play during the establishment of la-
tency. Here we used the murine gammaherpesvirus system to examine the expression of the la-
tency-associated M2 gene during latency and the induction of the CD8
 
1
 
 T cell response to this
protein. M2, in contrast to the M3 latency-associated antigen, was expressed at day 14 after in-
 
fection but was undetectable during long-term latency. The induction of the M2
 
91–99
 
/K
 
d
 
 CD8
 
1
 
T cell response was B cell dependent, transient, and apparently induced by the rapid increase in
latently infected cells around day 14 after intranasal infection. These kinetics were consistent
with a role in controlling the initial “burst” of latently infected cells. In support of this hypoth-
esis, adoptive transfer of an M2-specific CD8
 
1
 
 T cell line reduced the initial load of latently in-
fected cells, although not the long-term load. These data represent the first description of a la-
tent antigen-specific immune response in this model, and suggest that vaccination with latent
antigens such as M2 may be capable of modulating latent gammaherpesvirus infection.
Key words: gammaherpesvirus • virus latency • CD8
 
1
 
 T lymphocytes • viral antigens • viral 
load
 
Introduction
 
The CD8
 
1
 
 T cell response is known to be of critical impor-
tance for the control of gammaherpesvirus infections. In
both the human viruses, EBV and the Kaposi sarcoma–asso-
ciated herpesvirus (HHV-8), lytic and latent cycle proteins
are targets for the CD8
 
1
 
 T cell response (1, 2), and recent
data have shed light on the relative magnitude of the im-
mune response against different viral proteins. In the dra-
matic T cell response that occurs during primary EBV infec-
tion (infectious mononucleosis), up to 44% of CD8
 
1
 
 T cells
are specific for an epitope in the lytic phase protein BZLF1
(3). In contrast, only 1–2% of CD8
 
1
 
 T cells recognized an
epitope from the latency-associated EBV nuclear antigen
 
(EBNA)
 
1
 
 3A protein. In postconvalescent patients the re-
sponse to the BZLF1 epitope declines to 10–20%; however,
the response to the EBNA3A epitope remains at the same
level. Given the strong immune response to lytic phase anti-
gens, it seems likely that continual immune surveillance
serves to recognize cells reactivating from latency, thus lim-
iting the dissemination of the virus. In contrast, the role of
latent antigen-specific CD8
 
1
 
 T cells in the control of the
infection remains enigmatic. Unlike lytic antigen-specific T
cells, these cells have the potential to target latently infected
cells directly and to modulate the latent virus burden.
The early events after gammaherpesvirus infection have
been difficult to study in vivo, largely due to the lack of a
tractable animal model. Humans display clinical symptoms
of EBV infection several weeks after infection, a time when
latency has likely already been established. It is therefore
difficult to follow the onset of the immune reaction that is
induced in response to latently infected cells. An under-
standing of this response is critical if our aim is to under-
stand how the immune response can be harnessed to lower
the load of latently infected cells in infected individuals.
The murine gammaherpesvirus 68 (MHV-68) system of-
fers a very powerful tool to study fundamental aspects of
 
Address correspondence to David L. Woodland, The Trudeau Institute,
100 Algonquin Ave., Saranac Lake, NY 12983. Phone: 518-891-3080;
Fax: 518-891-5126; E-mail: dwoodland@trudeauinstitute.org
 
1
 
Abbreviations used in this paper: 
 
CFSE, carboxyfluorescein (diacetate)
succinimidyl ester; EBNA, EBV nuclear antigen; ELISPOT, enzyme-
linked immunospot; MHV-68, murine gammaherpesvirus 68; 
 
m
 
MT, B
cell–deficient; ORF, open reading frame; RT, reverse transcriptase.
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gammaherpesvirus pathogenesis. After intranasal inocula-
tion, the virus replicates productively in the lungs, then es-
tablishes a latent infection in lymphoid tissue, predomi-
nantly the spleen (4), although other cells can also maintain
a latent infection (5–8). Latently infected cells increase in
number rapidly up to 
 
z
 
14 d after infection, then they de-
cline over the subsequent 2 wk to a low level. A low-level
lytic replication can be detected in the spleen for 
 
z
 
1 mo
after infection, which may be due to spontaneous reactiva-
tion from latency (9). Several candidate latency-associated
genes have been identified (10–12), one of which, M2, has
been shown to be associated exclusively with latent infec-
tion. Transcription of the M2 gene was detected in all cells
of the latently infected cell line S11, whereas only a small
proportion of cells expressed lytic cycle proteins. M2 is not
expressed in lytically infected fibroblasts, but can be de-
tected in spleen cells from latently infected mice in the ab-
sence of lytic cycle transcripts (10). We also detected tran-
scription of a second putative latency-associated gene, M3,
in latently infected spleen cells, although this gene was not
uniformly expressed in latently infected S11 cells (10). Im-
portantly, we showed that M2 contains an epitope (M2
 
91–99
 
/
K
 
d
 
) recognized by CD8
 
1
 
 T cells (10). Therefore, using this
model system we can measure the kinetics of induction of
the latent antigen-specific CD8
 
1
 
 T cell response, and test
directly the impact of latent antigen-specific CD8
 
1
 
 T cells
during the infection.
In this study we report the kinetics of expression of the
latency-associated M2 and M3 genes, and profile the initia-
tion of the CD8
 
1
 
 T cell response to M2. We present data
showing that M2
 
91–99
 
/K
 
d
 
–specific CD8
 
1
 
 T cells can con-
tribute to the control of latently infected cells during the
establishment of latency.
 
Materials and Methods
 
Mice and Virus.
 
MHV-68 virus (clone G2.4) was originally
obtained from Prof. A.A. Nash (University of Edinburgh). Virus
was propagated and titered as described previously (4). BALB/c
mice were purchased from The Jackson Laboratory or Bantin and
Kingman. B cell–deficient (
 
m
 
MT) mice on a BALB/c back-
ground were bred at the Trudeau Institute Animal Breeding Fa-
cility from breeding pairs provided by Dr. W. Gerhard (The
Wistar Institute, Philadelphia, PA). Mice were infected intrana-
sally with 400 PFU or intraperitoneally with 10
 
6
 
 PFU of MHV-
68. All animal experiments were approved by The Trudeau Insti-
tute Animal Care and Use Committee.
 
Generation of the M2
 
91–99
 
/K
 
d
 
–specific CD8
 
1
 
 T Cell Line.
 
The
S11 tumor cell line has been described previously (13). Spleen
cells were prepared from BALB/c mice at 24 d after infection and
depleted of CD4
 
1
 
 and MHC class II
 
1
 
 cells using anti–mouse
CD4 (GK1.5, TIB207; American Type Culture Collection) and
anti–mouse MHC class II (TIB120; American Type Culture Col-
lection), followed by incubation with a mixture of anti–rat- and
anti–mouse-conjugated Dynabeads (Dynal). Magnetically labeled
cells were removed and the remaining cells were cultured with
X-irradiated (3,800 rads) S11 cells with 10 U/ml recombinant
human IL-2 (R&D Systems). Cells were restimulated with irradi-
ated S11 cells supplemented with irradiated BALB/c spleen
feeder cells and IL-2 every 5–8 d.
 
Chromium-release Assays.
 
Assays were performed as described
previously (14). In brief, target cells were loaded with 150 
 
m
 
Ci
Na
 
51
 
CrO
 
4 
 
with or without peptide for 18 h at 37
 
8
 
C. Target cells
were washed and incubated with graded numbers of effector cells
for 5 h at 37
 
8
 
C. Assays were performed in round-bottomed 96-
well plates and each well received 10
 
3
 
 target cells. Spontaneous
and maximum release were measured by incubation with me-
dium alone or 1% Triton X-100, respectively. The percentage of
specific release was calculated using the formula: % specific re-
lease 
 
5 
 
[(experimental 
 
2
 
 spontaneous)/(maximum 
 
2
 
 spontane-
ous)] 
 
3
 
 100.
 
Assays for Free and Latent Virus.
 
Assays were performed es-
sentially as described previously (4, 15). Plaque assay was used to
measure free virus in the lungs or spleen. Serial dilutions of ho-
mogenized lung tissue or freeze–thawed spleen tissue were added
to 3T3 monolayers in a minimal volume and left to adsorb for 1 h
before overlaying with carboxymethylcellulose. Monolayers were
fixed and stained after a 5-d incubation as described above. To
confirm that the freeze–thaw procedure used in the estimation of
spleen cell virus titer did not destroy the virus infectivity, we per-
formed a control experiment in which virus was added to either
medium alone or a spleen cell suspension. The titer obtained
from frozen samples was then compared with that obtained from
unfrozen samples. The freeze–thaw process reduced the titer by
only 10% (data not shown). Latent virus was measured using an
infective center assay. Graded numbers of spleen cells from in-
fected mice were added to monolayers of NIH 3T3 cells and
overlaid with carboxymethylcellulose. After 6 d, monolayers
were fixed with methanol and stained with Giemsa stain. Samples
of spleen cells were also subjected to freeze-thaw and used to
measure the titer of free virus in the spleen.
 
Intracellular Staining for IFN-
 
g
 
.
 
Spleen cells from BALB/c
mice infected with MHV-68 were stimulated in vitro with M2
 
91–99
 
peptide at a concentration of 1 
 
m
 
g/ml, then stained for the pres-
ence of intracellular IFN-
 
g 
 
according to previously published
protocols (16). In brief, spleen cells were incubated with peptide
plus 10 
 
m
 
g/ml brefeldin A and 10 U/ml IL-2 for 5 h. Fc binding
was blocked using anti–mouse CD16/CD32 (BD PharMingen)
and the cells were stained with Tricolor-conjugated anti-CD8
antibody (Caltag). After fixation with 2% formaldehyde, cells
were permeabilized with 0.5% saponin (Sigma-Aldrich), then
stained with anti–mouse IFN-
 
g
 
 or an isotype control IgG1 anti-
body (BD PharMingen) in the presence of 0.5% saponin. Samples
were analyzed on a Becton Dickinson FACScan™ flow cytome-
ter using CELLQuest™ software (Becton Dickinson). As a posi-
tive control, cells were treated with 50 ng/ml PMA plus 500 ng/ml
ionomycin. Peptide synthesis was performed either by New En-
gland Peptide Inc. (Fitchburg, MA) or by the Center for Biotech-
nology at St. Jude Children’s Research Hospital.
 
Carboxyfluorescein (Diacetate) Succinimidyl Ester Labeling and Cul-
ture Conditions.
 
Spleen cells were labeled with carboxyfluores-
cein (diacetate) succinimidyl ester (CFSE) by incubation with
0.5–0.7 
 
m
 
M CSFE diluted in HBSS for 10 min in the dark. Cells
were subsequently washed with HBSS or complete tumor me-
dium (17) before use. These cells were restimulated in vitro at a
10:1 ratio with irradiated S11 cells in the presence of IL-2 at 10
U/ml (R&D Systems) at a cell density of 10
 
6
 
/ml in 24-well
plates.
 
MHC Tetrameric Reagents and Analysis.
 
The construction of
folded MHC class I–peptide complexes and their tetramerization
have been described previously (18). Tetramers were generated
by the Molecular Biology Core Facility at The Trudeau Institute.
Two tetramers were used: K
 
d 
 
folded with M2
 
91–99 
 
peptide
 945
 
Usherwood et al.
(GFNKLRSTL) and K
 
d
 
 folded with HA518–528 (IYSTVASSL)
peptide derived from influenza A/PR/8/34. Tetramers were
stored as aliquots at 
 
2
 
20
 
8
 
C. Tetramers were titered using the
S11-specific CD8
 
1
 
 T cell line or spleen cells from mice trans-
genic for the K
 
d
 
/HA
 
518–528
 
 epitope (19); no cross-reactivity was
detected between the two tetramers. Spleen cells were depleted
of B cells by panning on goat anti–rat Ig (H
 
 
 
and L chain trans-
genes)-coated flasks before staining. Cells were incubated with
anti-CD16/CD32 Fc block (BD PharMingen) for 10 min on ice;
staining with tetrameric reagents took place for 1 h at room tem-
perature, followed by staining with anti-CD8–Tricolor on ice for
20 min. Stained samples were analyzed using a FACScan™ flow
cytometer and CELLQuest™ software (Becton Dickinson).
 
Enzyme-linked Immunospot Assay.
 
The relative frequencies of
IFN-
 
g
 
–secreting cells derived from the spleen were determined
after peptide stimulation in a standard enzyme-linked immuno-
spot (ELISPOT) assay system (16). In brief, 96-well Multiscreen-
HA nitrocellulose plates (Millipore) were coated overnight at 4
 
8
 
C
with 100
 
 
 
m
 
l per well of rat anti–mouse IFN-
 
g
 
 (clone R4-6A2;
BD PharMingen) at a concentration of 10 
 
m
 
g/ml. Responder
cells were prepared from spleens of BALB/c mice infected with
MHV-68 for 95 d, and enriched for CD8
 
1
 
 T cells by depleting
CD4
 
1
 
 and MHC class II
 
1
 
 cells using antibodies TIB120 and
GK1.5 followed by anti–rat Ig and anti–mouse Ig-coated Dyna-
beads (Dynal). The plates were then washed and blocked before
the addition of a graded number of responding cells: irradiated
(3,000 rads) syngeneic normal spleen cells, 10 
 
m
 
g/ml peptide
M2
 
91–99
 
, and 10 U/ml recombinant human IL-2. Plates were
then incubated overnight at 37
 
8
 
C and developed overnight with
a biotinylated detection antibody, rat anti–mouse IFN-
 
g
 
 (clone
XMG1.2; BD PharMingen), followed by streptavidin–horserad-
ish peroxidase (BD PharMingen) for 2 h at room temperature.
Visible spots of IFN-
 
g
 
–secreting cells were then enumerated us-
ing a SZH stereo zoom microscope system (Olympus). As a neg-
ative control in these assays, we used the HA
 
518–528
 
/K
 
d
 
 epitope
derived from influenza strain PR/8/34, which generally gave a
background of 
 
,
 
10 spots per well.
 
Reverse Transcriptase PCR Analysis from Infected Mouse Tissues.
 
Lungs and spleens were removed and snap frozen at 
 
2
 
70
 
8
 
C. A
portion of tissue from each organ was removed and total RNA
was prepared using RNAzol B (GIBCO BRL). RNA (2
 
 
 
m
 
g) was
treated with 10 U of RNase-free DNase 1 (Amersham Pharmacia
Biotech) at 37
 
8
 
C for 30 min. cDNA was synthesized at 42
 
8
 
C
with 200 U of Moloney murine leukemia virus reverse tran-
scriptase (RT) (Superscript II; GIBCO BRL) in the presence of
100 pM random primers (Roche Molecular Biochemicals) and
100 nM dNTPs (Amersham Pharmacia Biotech). A portion of
the cDNA (1.5 
 
m
 
l) was subjected to PCR with primer sets spe-
cific for the MHV-68 genes open reading frame (ORF)50, M2,
and M3 (Table I). Separate PCR reactions for murine 
 
b
 
-actin
were done for each cDNA sample. PCR reactions were carried
out with 1 U per reaction of Taq DNA polymerase (GIBCO
BRL) in the presence of 100 nM dNTP, 2.0 mM MgCl
 
2
 
, and 50
pmol of each primer in a total reaction volume of 50 
 
m
 
l. Cycling
parameters were the same for each primer set used and were:
96
 
8
 
C, 45 s; 45
 
8
 
C, 60 s; and 72
 
8
 
C, 120 s for 35 cycles with a final
extension at 72
 
8
 
C for 7 min. Reaction products were separated
by electrophoresis through 1% Tris-acetic acid–EDTA agarose
gels. After electrophoresis, PCR products were transferred to
HybondN
 
1
 
 (Amersham Pharmacia Biotech) in 0.4 M NaOH.
Blots were hybridized using standard techniques with double-
stranded DNA probes random prime labeled with [
 
a
 
-
 
32
 
P]dCTP.
Viral gene–specific DNA probes for labeling were obtained from
cloned viral DNA fragments that were cleaved from plasmid vec-
tors and purified before labeling. Murine 
 
b
 
-actin blots were hy-
bridized with a full-length chick 
 
b
 
-actin probe. A series of PCR
controls was incorporated as follows. To control for the carryover
of viral DNA, PCR was performed on cDNA synthesized in the
absence of RT. Controls for false positive signals included PCR
analysis of cDNA from spleen and lung tissue from uninfected
mice. Contamination was also controlled for with PCR per-
formed in the absence of cDNA. These control reactions were
negative in all cases. We determined the sensitivity of our PCR
reactions by diluting a known number of copies of template tar-
 
Table I. Primers Used for PCR Analysis
Gene Primer
Genome
coordinate* Sequence Product size 
bp
ORF50 Sense 68409 AAAAGTTCTGCATCCCAGACCC 293
Antisense 68701 AGGGCTAATGGGTGAAAATGGC
M2‡ Sense 4077 TAATAGGAAGACGTATCTCAGG 589
Antisense 5875 CTGCTTCCTTAGCCAGTCTC
M3 Sense 6566 TGGCACTCAAACTTGGTTGTGG 359
Antisense 6925 TAACAGGCAGATTGCCATTCCC
Murine b-actin‡ Sense – TGTGATGGTGGGAATGGGTCA 514
Antisense – TTTGATGTCACGCACGATTTC
*Genome coordinates as described by Virgin et al. (reference 34).
‡Primer sequences derived from different exons; therefore, spliced mRNA can be distinguished from unspliced genomic DNA.
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get in a background of uninfected mouse cDNA, then perform-
ing the PCR reaction. The sensitivity limit was found to be one
copy in all cases.
Results
Kinetics of Expression of Latency-associated Genes. In a
previous report we identified two genes, M2 and M3,
whose expression was associated with latent infection (10).
To investigate whether these genes were expressed long-
term during the latent infection, we isolated RNA from in-
fected mouse tissues at various times after infection and
performed RT-PCR to detect mRNA for M2 or M3. In
addition, we used primers for the lytic cycle transactivator
ORF50 and murine b-actin. It has been shown that
ORF50 (a homologue of the EBV rightward transactiva-
tor) is expressed at all stages of the virus productive cycle
and is responsible for reactivating virus from latency (20,
21). Therefore, analysis of ORF50 expression was per-
formed to detect low-level productive virus replication in
the samples. Expression of b-actin was monitored to con-
trol for RNA integrity and cDNA synthesis. We chose to
examine two tissues that have been shown to harbor a la-
tent infection: the spleen and the lungs (7).
As shown in Fig. 1, b-actin was expressed in all samples,
confirming the integrity of the PCR templates in all cases.
ORF50 gene expression was detected at days 7, 14, 21, and
32 after infection in all mice tested, consistent with previ-
ous data showing a low-level reactivation of virus in the
spleen during the first month after infection (9). By 10 mo
after infection we observed no ORF50 expression, indicat-
ing an undetectable level of productive virus replication at
this time. RNA encoding M3 was detected at all times
tested, although expression was sporadic at 10 mo after in-
fection. In contrast, M2 expression followed a different
pattern. It was detectable in only one of three spleens and
one of three lungs at day 7 after infection; however, by 14 d
there was expression in three of three lungs and two of
three spleens. M2 expression declined by day 21 after in-
fection (zero of three spleens and one of three lungs), and
was detectable in only one of four spleens at day 32. No
M2 expression was detectable at 10 mo after infection in
either spleens or lungs. Therefore, these data showed that
(a) there was a difference in the kinetics of M2 and M3 ex-
pression in vivo during latent infection, and (b) M2 expres-
sion appeared to be transient and no longer expressed in
the majority of mice by day 21 after infection.
The M291–99/Kd–specific CD81 T Cell Response Is Induced
during the Establishment of Latency. We have shown previ-
ously that the M2 protein is a target for the CD81 T cell
response, and we mapped the M291–99/Kd epitope that is
recognized (10). As we established that M2 expression was
transient, we wished to determine the longevity of the
M291–99/Kd–specific CD81 T cell response. We sampled
spleen cells from mice at different times after intranasal in-
fection with MHV-68 and measured the frequency of cells
that synthesized IFN-g in response to M291–99 peptide. As
shown in Fig. 2 A, the response was not detectable until 16 d
after infection, when it rose rapidly to z3.5% of CD81
T cells. However, the response was short lived and de-
clined by day 21 after infection. It was possible that the
downregulation in this response was not due to a loss of
M291–99/Kd–specific CD81 T cells but rather to these cells
failing to produce IFN-g. To resolve this issue, we synthe-
sized a tetrameric Kd reagent folded with M291–99 peptide
that specifically bound M291–99/Kd–specific CD81 T cells.
This reagent did not bind naive CD81 T cells or a CD81
T cell line of an irrelevant specificity (data not shown).
Detection of M291–99/Kd–specific CD81 T cells using the
tetrameric reagent showed similar kinetics to the IFN-g
staining (Fig. 2 C), demonstrating that this response is de-
tectable only during a very narrow time frame in the
spleen, between days 16 and 20 after infection. This is co-
incident with the decline in numbers of latently infected
cells in the spleen. In contrast to lytic antigen–specific
epitopes in C57BL/6 mice, we did not detect significant
numbers (,1% of CD81 T cells) of M291–99/Kd–specific
CD81 T cells in the bronchoalveolar lavage during the
acute respiratory infection using the tetrameric reagent
(data not shown).
To determine whether the kinetics of the M291–99/Kd–
specific CD81 T cell response were merely a reflection of
the CD81 T cell response to this virus as a whole, we also
measured IFN-g production from spleen cells stimulated
with PMA and ionomycin. These reagents induce IFN-g
production from all activated T cells, and therefore allowed
us to measure the proportion CD81 T cells that were acti-
Figure 1. The kinetics of expression of latency associated genes in
vivo. Mice were infected intranasally with MHV-68 for either 7, 14, 21,
or 32 d, or 10 mo, as indicated. Spleens and lungs were then sampled and
total RNA was analyzed by RT-PCR followed by Southern blotting
and autoradiography. Primers and probes specific for ORF50, M2, M3,
and b-actin were used as indicated. The numbers at the bottom of the
figure refer to individual mice. The asterisks in two of the panels highlight
the position of weak positive reactions. Several control reactions were
performed that were negative in all cases (data not shown). The controls
were as follows: PCR in the absence of RT, RT-PCR of tissue from un-
infected mice, and PCR performed in the absence of cDNA.
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vated. As shown in Fig. 2 B, this analysis revealed strikingly
different kinetics. A very high proportion of the CD81 T
cell compartment was activated by day 14 after infection,
and the response remained high for .30 d after infection.
These results are consistent with previous reports detailing
the mononucleosis-like syndrome that develops in response
to MHV-68 infection (22, 23). Therefore, the M291–99/Kd–
specific CD81 T cell response was unusual in that it
emerged relatively late (day 16) then declined rapidly only
4–5 d later to a level below the detection limit of these as-
says. Thus, the kinetics of this response were consistent
with M291–99/Kd–specific CD81 T cells contributing to the
reduction in titer of latently infected cells after day 14 after
infection.
Memory Is Established to the M291–99/Kd Epitope. The
kinetics of the M291–99/Kd–specific CD81 T cell response
suggested that it was an effector response in the spleen. We
thus addressed the question of whether memory was estab-
lished to this epitope after the decline in numbers of M291–99/
Kd–specific CD81 T cells in the spleen. Therefore, we
restimulated spleen cells from infected mice in vitro with
the latently infected S11 cell line and then performed a
51Cr-release assay to test for cytotoxic activity. Cultures es-
tablished from mice infected for 20, 47, or 68 d after infec-
tion all specifically killed targets pulsed with the M291–99
peptide but not unpulsed cells (Fig. 3). This demonstrated
that M291–99/Kd–specific CD81 T cells persist in the in-
fected mouse after the decline in numbers at day 21 after
infection, and that a low-level memory is established to the
M291–99/Kd epitope. In addition, it shows that these mem-
ory cells can be reactivated in vitro and display effector
function. To accurately quantitate the level of memory that
was established to this epitope, we used the IFN-g
ELISPOT technique using spleen cells from mice infected
with MHV-68 for 95 d. This revealed that the frequency of
M291–99/Kd–specific cells among CD81 T cells was 1/3,300
(n 5 4, range 1/2,300–1/4,400).
Efficient Induction of the M291–99/Kd–specific CD81 T Cell
Response Requires B Cells. B lymphocytes have an impor-
tant role in MHV-68 pathogenesis. They are a major target
cell for viral latency (24, 25) and in addition are able to
suppress the extent of reactivation from latency (6, 7),
probably through the production of a neutralizing anti-
body. Therefore, we wished to investigate whether B cells
were necessary for the priming of the M291–99/Kd–specific
CD81 T cell response. To study this we infected mMT
mice on a BALB/c background and monitored their ability
to mount a response to the M291–99/Kd epitope.
In initial experiments we observed a smaller population
of M291–99/Kd tetramer–positive cells in the spleens of
mMT mice compared with BALB/c mice at day 17 after
intranasal infection (data not shown); however, the sensi-
tivity limit of tetramer staining was relatively low (z0.5%).
Therefore, we chose to restimulate spleen cells from in-
fected mice in vitro with the latently infected S11 cell line,
then stain them with the M291–99/Kd tetramer. The expan-
sion in the number of M291–99/Kd–specific T cells allowed
us to detect even a small response against this epitope.
Spleens were taken at days 23–25 after infection because
we wished to avoid any activation-induced cell death that
Figure 2. The kinetics of the M291–99/Kd–specific CD81 T cell re-
sponse. Spleen cells from BALB/c mice infected intranasally with MHV-
68 were stimulated in vitro with either M291–99 peptide (A) or PMA and
ionomycin (B). The data represent the proportion of CD81 T cells that
produced IFN-g expressed as a percentage of total CD81 T cells. Each
point represents one individual mouse, and the data presented represent
pooled data from five independent infections. (C) The staining of spleen
cells with an M291–99/Kd–specific tetrameric reagent. The data represent
the proportion of tetramer-positive CD81 T cells as a percentage of total
CD81 T cells, and each point represents an individual mouse. Note the
different x-axis scale relative to A and B. An irrelevant tetramer (Flu
HA518–528/Kd) stained ,0.5% of CD81 cells.
Figure 3. Memory is established to the
M291–99/Kd epitope. Spleen cells from
BALB/c mice infected intranasally with
MHV-68 were restimulated in vitro with
irradiated S11 cells and IL-2 for 7 d. These
cells were then tested for M291–99Kd–specific
cytotoxicity using BALB/c 3T3 target cells
pulsed with M291–99 peptide or no peptide.
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may occur if the restimulation was performed during the
putative effector phase of the response, between 16 and 20 d
after infection. To measure cell proliferation, spleen cells
were labeled with CFSE, a fluorescent dye that is progres-
sively diluted with each cell division. As shown in Fig. 4, a
substantial number of M291–99/Kd tetramer–positive cells
was present using spleen cells taken from intranasally in-
fected BALB/c mice. However, a much smaller tetramer–
positive population (10-fold less) was observed using spleen
cells from intranasally infected mMT mice, demonstrating
that these mice made a very weak CD81 T cell response to
this epitope. This indicated that B cells are needed for effi-
cient priming of the M291–99/Kd–specific CD81 T cell re-
sponse.
We and others have shown that after intranasal infection
of mMT mice, there was little or no latent virus detected
in the spleen (6, 24). In contrast, a latent infection is estab-
lished in the spleen after intraperitoneal infection (26).
These data can be reconciled by our previous studies
showing that B cells are important in the traffic of virus
between the lung and spleen during latency (7). We con-
cluded that one role of B cells after intranasal infection
may be to traffic the virus to the spleen, where it can infect
more B cells and also other cells such as macrophages (5),
dendritic cells (8), and lung epithelial cells (7). In contrast,
intraperitoneal infection leads to a direct infection of the
spleen, bypassing the need for B cells. Therefore, we tested
whether intraperitoneal infection of mMT mice restored
their ability to prime the M291–99/Kd–specific CD81 T cell
response. Infection by this route primed a response of sim-
ilar magnitude to that observed using the intranasal route
in BALB/c mice (Fig. 4); however, there was still a
marked deficit in this response in mMT mice. These data
show that in the absence of B cells the M291–99/Kd–specific
CD81 T cell response is not primed efficiently, even when
the latent infection is established efficiently in non-B cells.
An M291–99/Kd–specific CD81 T Cell Line Can Reduce the
Number of Latently Infected Cells. The kinetics of the
M291–99/Kd–specific immune response were consistent with
a role for these cells in the control of the initial “burst” of
latently infected cells. After intranasal infection, free virus is
cleared from the lungs by day 7–10 after infection, then the
titer of latent virus begins to increase in the spleen. This
peaks at day 14 after infection, at z1 infective center per
104 spleen cells, then declines over the subsequent 2 wk to
z1 infective center per 107 spleen cells (4). Therefore, it
seemed likely that the M291–99/Kd–specific CD81 T cell re-
sponse was induced by the large increase in latently in-
fected cells around day 14 after infection and subsequently
killed many of these cells between days 16 and 20 after in-
fection, contributing to the decline in latent virus titer.
Therefore, we took an adoptive transfer approach to de-
termine whether the M291–99/Kd–specific CD81 T cell re-
sponse has the ability to influence the load of latently in-
fected cells during the early stages of latency. As detailed in
a previous report, we generated an M291–99/Kd–specific
CD81 T cell line from infected BALB/c mice, which
killed latently infected S11 cells, target cells pulsed with
M291–99 peptide, but not unpulsed target cells (10). We
then transferred either 107 M291–99/Kd–specific CD81 T
cell line cells (7 d after their last stimulation with antigen)
or medium alone into BALB/c mice and infected the mice
intranasally with MHV-68 on the same day. Spleens were
removed at various times after infection, and we measured
the numbers of latently infected cells. As shown in Table II,
recipients of the M291–99/Kd–specific CD81 T cell line ex-
hibited a 30–80-fold reduction in the number of latently
infect cells at day 14 after infection compared with control
Figure 4. The M291–99/Kd–specific
CD81 T cell response is not primed effi-
ciently in mMT mice. BALB/c or mMT
mice were infected either intranasally (i.n.)
with 400 PFU or intraperitoneally (i.p.)
with 106 PFU MHV-68, then spleens were
removed at 23–25 d after infection. Spleen
cell suspensions were labeled with the fluo-
rescent dye CFSE then restimulated in vitro
with irradiated S11 cells in the presence of
10 U/ml human recombinant IL-2 for 4 d.
Cultures were then stained with anti-CD8
and either M291–99/Kd tetramer or a control
influenza HA518–528/Kd tetramer. The data
show CFSE and tetramer staining gated on
live CD81 cells. The numbers show the
percentage of tetramer-positive CFSElo cells
among CD81 cells (boxed). For intranasal
infection, the ranges were 7.6–13.4% for
BALB/c mice and 0.6–1.5% for mMT
mice; for intraperitoneal infection, the
ranges were 5.4–15.1% for BALB/c mice
and 0.6–1.0% for mMT mice. Similar data
were obtained on days 17–126 after infec-
tion. In general, three to four mice were
used per experimental group.
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mice. To determine the antigen specificity of this effect, we
performed an additional experiment using a T cell line spe-
cific for the influenza HA518–528/Kd epitope. Adoptive
transfer of this line had no effect on the latent virus titer in
the spleen at 14 d after infection (data not shown).
The reduction in latent virus at this time cannot be ac-
counted for by a reduction in the initial viral load during
the acute lung infection, as we observed no significant dif-
ference in lung virus titers between the two groups on day
7 after infection (Fig. 5). The reduction in latently infected
cells was only observed at 14 d after infection, when peak
levels of latent virus are detected after intranasal infection,
whereas at days 21 or 28 after infection there was no signif-
icant difference between control and recipient groups (Ta-
ble II). This shows that CD81 T cells specific for the M291–99/
Kd epitope can contribute to the control of latently infected
cells during the establishment of latency.
Discussion
We present a profile of the CD81 T cell response to a la-
tency-associated gammaherpesvirus antigen in the MHV-
68 system. The response to the M291–99/Kd epitope fol-
lowed unusual kinetics, being present for only 4–5 d before
declining to a low level (,0.5% of CD81 T cells). Thus,
the M291–99/Kd–specific response appears to be induced by
the rapid rise in latently infected cells that peaks at z14 d
after infection. The peak of the M291–99/Kd–specific T cell
response coincides with the reduction in the number of la-
tently infected cells from the spleen (4). This contrasts with
the CD81 T cell response to lytic cycle epitopes in
C57BL/6 mice, which appears much earlier in the spleen
(day 12) and declines slower, around day 30–40 after infec-
tion (27). In addition, we have shown that the adoptive
transfer of an M291–99/Kd–specific CD81 T cell line can re-
duce the titer of latently infected cells at 14 d after infec-
tion. Taken together, these data suggest that the M291–99/
Kd–specific T cell response contributes to the control of la-
tently infected cells during the first 2–3 wk after infection.
These are the first studies to show unambiguously that la-
tent antigen-specific CD81 T cells have the ability to con-
trol a latent gammaherpesvirus infection.
The reason for the rapid decline in the M291–99/Kd–spe-
cific response is likely due to the absence of antigen, since,
as shown in Fig. 1, transcripts for M2 had declined dramat-
ically by 32 d after infection. In contrast, expression of both
ORF50 (a lytic cycle product) and M3 (a latency-associated
product) persisted through this time point. This pattern of
Table II. The Effect of Adoptive Transfer of an M291–99/Kd–specific CD81 T Cell Line on the Titer of Latent Virus in the Spleen
Experiment Time after infection Treatment* Latent virus titer‡ P value§ Fold reduction
d
1 7 – 19.0 (19.1)
7 Anti-M2 4.7 (3.0) 0.268 4.0
14 – 3,816.7 (1,147.1)
14 Anti-M2 46.7 (32.5) 0.0047 81.7
2 14 – 4,812.5 (4,411.6)
14 Anti-M2 63.0 (58.0) 0.075 76.4
3 14 – 2,525.0 (1,533.2)
14 Anti-M2 81.6 (40.5) 0.019 30.9
21 – 155.3 (104.8)
21 Anti-M2 346.7 (195.0) 0.155 ,1
4 21 – 99.8 (68.5)
21 Anti-M2 79.8 (15.8) 0.650 1.25
5 21 – 112.3 (159.9)
21 Anti-M2 110.3 (86.0) 0.986 1.02
28 – 35.0 (20.1)
28 Anti-M2 27.2 (32.9) 0.742 1.29
*Mice received either medium alone (–) or an M291–99/Kd–specific CD8+ T cell line (anti-M2).
‡Shown are mean values with SD in parentheses; three to four mice were used in each group.
§P values were determined using the Student’s t test; values ,0.05 represent statistical significance.
Figure 5. Adoptive transfer of
an M291–99/Kd–specific CD81 T
cell line has no effect on the
acute lung infection. BALB/c
mice received either 107 M291–99/
Kd–specific CD81 T cell line
cells or medium alone intrave-
nously and were then infected
intranasally with MHV-68. At 7 d
after infection, lungs were re-
moved and the titer of virus was
assayed. The results show the mean titer of three animals per group, and
error bars show 1 SD. Data are representative of three experiments.
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expression therefore correlates with the decline in the M2
response and the longer-lived persistence of the response to
lytic cycle antigens. It is possible that the virus downregu-
lates expression of M2 to evade the immune response, and
that this forms part of a switch in the program of latency.
An analogous phenomenon is believed to occur in EBV in-
fection. When B cells are first infected, the virus is thought
to enter the latency III or “growth program”: it expresses
several immunogenic proteins, and there is extensive pro-
liferation of latently infected cells. The immune response
then kills many infected cells, and the remaining latently
infected B cells enter a more restricted program of gene ex-
pression. Recent studies in the MHV-68 system support
this idea, showing that there was a disparity between the
number of virus genome-positive cells and the number of
cells capable of reactivation (6). The proportion of cells ca-
pable of reactivation decreased with time after infection,
suggesting that there is a temporal shift in the state of la-
tency, moving towards a latent state that does not reactivate
in vitro. This change in the character of latency may re-
strict the expression of M2. Our data showing that M2 and
M3 genes are not downregulated with the same kinetics
support the idea of multiple states of latency. An alternative
explanation for the switch to a more restricted program of
MHV-68 latency is that M291–99/Kd–specific response
eliminates all cells expressing M2 and therefore selects for a
subpopulation of cells that is already in a different latent
gene expression program.
Our data show that B cell–deficient mice do not mount
an efficient CD81 T cell response against M2. This implies
that B cells are the major antigen-presenting cell type pre-
senting the M291–99/Kd epitope. The most straightforward
explanation for this is that a latent infection of B cells is re-
quired for the expression of M2 and correct presentation to
T cells. We do not present evidence that directly shows the
transcription of the M2 gene in different cell types; how-
ever, our data imply that other latently infected cell types
such as macrophages (5) and dendritic cells (8) either (a) do
not express M2, (b) do not process it in the same way, or
(c) express such low levels that it leads to poor immunolog-
ical priming. A report detailing the detection of M2
mRNA from intraperitoneally infected mMT mice (11)
implies the protein is made in the absence of B cells, indi-
cating that (b) or (c) above may be the more likely explana-
tion.
There is a great deal of interest in developing vaccines
against the human gammaherpesviruses. Most EBV vaccine
strategies to date have focused on blocking the primary in-
fection by the generation of antibody response to glycopro-
tein 340/220, the virus ligand for the cellular receptor
CD21. An additional suggested approach is to vaccinate a
CTL response to lytic cycle proteins (28). The disadvantage
with both of these approaches is that an immune response
directed towards lytic cycle proteins cannot recognize la-
tently infected cells, so that once latency is established the
virus has effectively escaped from the immune response.
This has been shown to be true for MHV-68, in which
vaccination with immunogenic lytic cycle proteins can re-
duce the lung virus titer and splenomegaly, but the virus
still establishes a latent infection efficiently (29, 30).
An alternative approach is to vaccinate against latency-
associated antigens (31), which will target latently infected
cells directly and may lead to a lower latent virus load. This
approach will not prevent initial infection; however, the
majority of serious diseases associated with human gamma-
herpesviruses are a consequence of long-term latent infec-
tion. Indeed, the risk of developing certain EBV-associated
malignancies has been correlated with the load of latent vi-
rus (32, 33). Given the potency of the M291–99/Kd–specific
CD81 T cell line at reducing the day 14 latent virus titer,
M2 is a promising vaccine candidate in the MHV-68
model system. Although M2 is only expressed transiently in
the spleen, it may nevertheless be expressed by all latently
infected cells during the early phase of latency, thus making
them targets for the CD81 T cell response. Therefore, it is
conceivable that if there is a sufficiently rapid and vigorous
M291–99/Kd–specific CD81 T cell response in vaccinated
animals, then it may be able to destroy a significant number
of latently infected cells and perhaps reduce the long-term
burden of latent virus. We observed only a transient de-
crease in the number of latently infected cells in our adop-
tive transfer system, but we do not know how long these
cells survive in vivo, or the numbers of cells that persist in
the spleen after transfer. Given the limitations of this adop-
tive transfer system, we are currently addressing whether
active vaccination against M2 can provide a longer-lasting
reduction in latently infected cell numbers.
In conclusion, we have presented the first description of
the CD81 T cell response to a latency-associated antigen in
the MHV-68 model system. This underlines the utility of the
MHV-68 model as a very powerful tool that allows us to
discover general mechanisms by which this class of virus is
controlled in the host, and should illuminate the pathogen-
esis of gammaherpesvirus infections of importance for vet-
erinary or human medicine. This report should lead to a
better understanding of the role latent antigen-specific T
cells play in the immune response to gammaherpesviruses,
and experimentally determine whether vaccination with la-
tent antigens is a feasible strategy for combating this signifi-
cant class of pathogen.
We thank Scottie Adams and Tim Miller of the Trudeau Institute Mo-
lecular Biology Core Facility for the generation of tetrameric reagents.
This work was supported by National Institutes of Health grants
AI37597 (D.L. Woodland) and AI42927 (M.A. Blackman), The
Trudeau Institute, the Cancer Research Campaign (UK), and The
Royal Society. J.P. Stewart is a Royal Society University Research
Fellow.
Submitted: 10 May 2000
Revised: 9 August 2000
Accepted: 15 August 2000
References
1. Osman, M., T. Kubo, J. Gill, F. Neipel, M. Becker, G.
Smith, R. Weiss, B. Gazzard, C. Boshoff, and F. Gotch.
951 Usherwood et al.
1999. Identification of human herpesvirus 8-specific cyto-
toxic T-cell responses. J. Virol. 73:6136–6140.
2. Rickinson, A.B., and D.J. Moss. 1997. Human cytotoxic T
lymphocyte responses to Epstein-Barr virus infection. Annu.
Rev. Immunol. 15:405–431.
3. Callan, M.F., L. Tan, N. Annels, G.S. Ogg, J.D. Wilson,
C.A. O’Callaghan, N. Steven, A.J. McMichael, and A.B.
Rickinson. 1998. Direct visualization of antigen-specific
CD81 T cells during the primary immune response to Ep-
stein-Barr virus in vivo. J. Exp. Med. 187:1395–1402.
4. Sunil-Chandra, N.P., S. Efstathiou, J. Arno, and A.A. Nash.
1992. Virological and pathological features of mice infected
with murine gamma-herpesvirus 68. J. Gen. Virol. 73:2347–
2356.
5. Weck, K.E., S.S. Kim, H.I. Virgin, and S.H. Speck. 1999.
Macrophages are the major reservoir of latent murine gam-
maherpesvirus 68 in peritoneal cells. J. Virol. 73:3273–3283.
6. Weck, K.E., S.S. Kim, H.I. Virgin, and S.H. Speck. 1999. B
cells regulate murine gammaherpesvirus 68 latency. J. Virol.
73:4651–4661.
7. Stewart, J.P., E.J. Usherwood, A. Ross, H. Dyson, and T.
Nash. 1998. Lung epithelial cells are a major site of murine
gammaherpesvirus persistence. J. Exp. Med. 187:1941–1951.
8. Flano, E., S.M. Husain, J.T. Sample, D.L. Woodland, and
M.A. Blackman. 2000. Latent murine gammaherpesvirus in-
fection is established in activated B cells, dendritic cells, and
macrophages. J. Immunol. 165:1074–1081.
9. Liu, L., E. Flano, E.J. Usherwood, S. Surman, M.A. Black-
man, and D.L. Woodland. 1999. Lytic cycle T cell epitopes
are expressed in two distinct phases during MHV-68 infec-
tion. J. Immunol. 163:868–874.
10. Husain, S.M., E.J. Usherwood, H. Dyson, C. Coleclough,
M.A. Coppola, D.L. Woodland, M.A. Blackman, J.P. Stew-
art, and J.T. Sample. 1999. Murine gammaherpesvirus M2
gene is latency-associated and its protein a target for CD81 T
lymphocytes. Proc. Natl. Acad. Sci. USA. 96:7508–7513.
11. Virgin, H.W., IV, R.M. Presti, X.Y. Li, C. Liu, and S.H.
Speck. 1999. Three distinct regions of the murine gamma-
herpesvirus 68 genome are transcriptionally active in latently
infected mice. J. Virol. 73:2321–2332.
12. Simas, J.P., D. Swann, R. Bowden, and S. Efstathiou. 1999.
Analysis of murine gammaherpesvirus-68 transcription during
lytic and latent infection. J. Gen. Virol. 80:75–82.
13. Usherwood, E.J., J.P. Stewart, and A.A. Nash. 1996. Charac-
terization of tumor cell lines derived from murine gamma-
herpesvirus-68-infected mice. J. Virol. 70:6516–6518.
14. Cole, G.A., V.K. Clements, E.P. Garcia, and S. Ostrand-
Rosenberg. 1987. Allogeneic H-2 antigen expression is insuf-
ficient for tumor rejection. Proc. Natl. Acad. Sci. USA. 84:
8613–8617.
15. Cardin, R.D., J.W. Brooks, S.R. Sarawar, and P.C. Doherty.
1996. Progressive loss of CD81 T cell–mediated control of a
gamma-herpesvirus in the absence of CD41 T cells. J. Exp.
Med. 184:863–871.
16. Murali-Krishna, K., J.D. Altman, M. Suresh, D.J. Sourdive,
A.J. Zajac, J.D. Miller, J. Slansky, and R. Ahmed. 1998.
Counting antigen-specific CD8 T cells: a reevaluation of by-
stander activation during viral infection. Immunity. 8:177–
187.
17. Kappler, J.W., B. Skidmore, J. White, and P. Marrack. 1981.
Antigen-inducible, H-2–restricted, interleukin-2–producing
T cell hybridomas. Lack of independent antigen and H-2
recognition. J. Exp. Med. 153:1198–1214.
18. Altman, J.D., P.H. Moss, P.R. Goulder, D.H. Barouch,
M.G. McHeyzer-Williams, J.I. Bell, A.J. McMichael, and
M.M. Davis. 1996. Phenotypic analysis of antigen-specific T
lymphocytes. Science. 274:94–96.
19. Morgan, D.J., R. Liblau, B. Scott, S. Fleck, H.O. McDevitt,
N. Sarvetnick, D. Lo, and L.A. Sherman. 1996. CD81 T
cell-mediated spontaneous diabetes in neonatal mice. J. Im-
munol. 157:978–983.
20. Mackett, M., J.P. Stewart, S. de V. Pepper, M. Chee, S. Ef-
stathiou, A.A. Nash, and J.R. Arrand. 1997. Genetic content
and preliminary transcriptional analysis of a representative re-
gion of murine gammaherpesvirus 68. J. Gen. Virol. 78:
1425–1433.
21. Wu, T.T., E.J. Usherwood, J.P. Stewart, A.A. Nash, and R.
Sun. 2000. Rta of murine gammaherpesvirus 68 reactivates
the complete lytic cycle from latency. J. Virol. 74:3659–3667.
22. Coppola, M.A., E. Flano, P. Nguyen, C.L. Hardy, R.D.
Cardin, N. Shastri, D.L. Woodland, and M.A. Blackman.
1999. Apparent MHC-independent stimulation of CD81 T
cells in vivo during latent murine gammaherpesvirus infec-
tion. J. Immunol. 163:1481–1489.
23. Tripp, R.A., A.M. Hamilton-Easton, R.D. Cardin, P.
Nguyen, F.G. Behm, D.L. Woodland, P.C. Doherty, and
M.A. Blackman. 1997. Pathogenesis of an infectious mono-
nucleosis-like disease induced by a murine gamma-herpesvi-
rus: role for a viral superantigen? J. Exp. Med. 185:1641–
1650.
24. Usherwood, E.J., J.P. Stewart, K. Robertson, D.J. Allen, and
A.A. Nash. 1996. Absence of splenic latency in murine gam-
maherpesvirus 68-infected B cell-deficient mice. J. Gen. Vi-
rol. 77:2819–2825.
25. Sunil-Chandra, N.P., S. Efstathiou, and A.A. Nash. 1992.
Murine gammaherpesvirus 68 establishes a latent infection in
mouse B lymphocytes in vivo. J. Gen. Virol. 73:3275–3279.
26. Weck, K.E., M.L. Barkon, L.I. Yoo, S.H. Speck, and H.I.
Virgin. 1996. Mature B cells are required for acute splenic in-
fection, but not for establishment of latency, by murine gam-
maherpesvirus 68. J. Virol. 70:6775–6780.
27. Stevenson, P.G., G.T. Belz, J.D. Altman, and P.C. Doherty.
1999. Changing patterns of dominance in the CD81 T cell
response during acute and persistent murine gamma-herpes-
virus infection. Eur. J. Immunol. 29:1059–1067.
28. Khanna, R., M. Sherritt, and S.R. Burrows. 1999. EBV
structural antigens, gp350 and gp85, as targets for ex vivo vi-
rus-specific CTL during acute infectious mononucleosis: po-
tential use of gp350/gp85 CTL epitopes for vaccine design. J.
Immunol. 162:3063–3069.
29. Liu, L., E.J. Usherwood, M.A. Blackman, and D.L. Wood-
land. 1999. T-cell vaccination alters the course of murine
herpesvirus 68 infection and the establishment of viral latency
in mice. J. Virol. 73:9849–9857.
30. Stevenson, P.G., G.T. Belz, M.R. Castrucci, J.D. Altman,
and P.C. Doherty. 1999. A gamma-herpesvirus sneaks
through a CD81 T cell response primed to a lytic-phase
epitope. Proc. Natl. Acad. Sci. USA. 96:9281–9286.
31. Moss, D.J., C. Schmidt, S. Elliott, A. Suhrbier, S. Burrows,
and R. Khanna. 1996. Strategies involved in developing an
effective vaccine for EBV-associated diseases. Adv. Cancer
Res. 69:213–245.
32. Savoie, A., C. Perpete, L. Carpentier, J. Joncas, and C. Alfi-
eri. 1994. Direct correlation between the load of Epstein-
Barr virus-infected lymphocytes in the peripheral blood of
pediatric transplant patients and risk of lymphoproliferative
952 CD81 T Cells Control Gammaherpesvirus Latency
disease. Blood. 83:2715–2722.
33. Riddler, S.A., M.C. Breinig, and J.L. McKnight. 1994. In-
creased levels of circulating Epstein-Barr virus (EBV)-
infected lymphocytes and decreased EBV nuclear antigen
antibody responses are associated with the development of
posttransplant lymphoproliferative disease in solid-organ trans-
plant recipients. Blood. 84:972–984.
34. Virgin, H.W., IV, P. Latreille, P. Wamsley, K. Hallsworth,
K.E. Weck, A.J. Dal Canto, and S.H. Speck. 1997. Com-
plete sequence and genomic analysis of murine gammaher-
pesvirus 68. J. Virol. 71:5894–5904.
